EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Efficacy and Safety of Brain Radiotherapy Combined With Immune Checkpoint Inhibitors ( ICIs ) for Small‐Cell Lung Cancer ( SCLC ) Patients With Brain Metastases ( BMs )

Jie Xu iD, Yanling Yang, Tingting Chen, Dongmin Liu, Yajing Yuan, Liming Xu

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Jie Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center fo…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Brain Neoplasms, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China (No. 82373194).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was designed to evaluate the efficacy and safety of brain radiotherapy combined with immune checkpoint inhibitors (ICIs) retrospectively in small‐cell lung cancer (SCLC) patients with brain metastases (BMs).

Methods

A retrospective analysis was conducted on 42 SCLC patients with BMs, who received brain radiotherapy combined with ICIs at our Hospital from 2020 to 2024. They received chemotherapy plus ICIs regimens and brain radiotherapy, and received concurrent/sequential thoracic radiotherapy. This study investigated the forms of WBRT vs. WBRT+ simultaneous integrated boost (SIB, different doses of radiation being delivered simultaneously to different parts of the tumor) combined with ICIs on overall survival (OS), intracranial local control (iLC), and radiotherapy adverse reactions (side effection). The Kaplan–Meier method was used for survival rate analysis. The log‐rank test was used to compare the survival curves between different groups, and the chi‐square (χ 2 ) test was used to compare categorical data.

Results

In all the patients, the median follow‐up time was 19.2 (range: 9.79–36.8) months. The 2‐year OS rate and iLC rate were 42.3% and 68.8%, respectively. A total of 26 patients died of disease progression; 2 patients developed radiation‐induced brain necrosis. The results showed that there was no significant difference in radiation‐induced brain necrosis between the two groups. The WBRT patients suffered high rates of headache, dizziness, nausea, and radiodermatitis. The 2‐year OS and iLC were brilliant.

Conclusions

When brain radiotherapy combined with ICIs, even WBRT or WBRT + SIB had well OS and iLC with tolerable side reactions. Its indications needed to be considered from multiple perspectives. Further evaluation of brain radiotherapy combined with ICIs in SCLC BMs is required. Further prospective studies should be conducted to verify the conclusions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaBrain NeoplasmsImmune Checkpoint InhibitorsLung NeoplasmsCranial IrradiationHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultCombined Modality Therapy

Stichwörter der Autor:innen

brain metastasescarcinomaefficacyradiotherapysafetysmall‐cell lung cancer

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laborator…
  • Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Rese…
  • Department of Anesthesia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Cen…
  • Department of Radiation Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.

ORCID-Profile: Jie Xu

Förderung

  • the National Natural Science Foundation of China (No. 82373194)

Zitieren

APA

Xu, J., Yang, Y., Chen, T., Liu, D., Yuan, Y., & Xu, L. (2025). The Efficacy and Safety of Brain Radiotherapy Combined With Immune Checkpoint Inhibitors ( ICIs ) for Small‐Cell Lung Cancer ( SCLC ) Patients With Brain Metastases ( BMs ). Thoracic Cancer. https://doi.org/10.1111/1759-7714.70112

Vancouver

Xu J, Yang Y, Chen T, Liu D, Yuan Y, Xu L. The Efficacy and Safety of Brain Radiotherapy Combined With Immune Checkpoint Inhibitors ( ICIs ) for Small‐Cell Lung Cancer ( SCLC ) Patients With Brain Metastases ( BMs ). Thoracic Cancer. 2025. doi:10.1111/1759-7714.70112

BibTeX
@article{Xu2025,
  author = {Xu, Jie and Yang, Yanling and Chen, Tingting and Liu, Dongmin and Yuan, Yajing and Xu, Liming},
  title = {The Efficacy and Safety of Brain Radiotherapy Combined With Immune Checkpoint Inhibitors ( ICIs ) for Small‐Cell Lung Cancer ( SCLC ) Patients With Brain Metastases ( BMs )},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70112}
}
Kostenlos starten →